Mode
Text Size
Log in / Sign up
N/A N=95 Screening

Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System

Gastrointestinal Disease · Colorectal Cancer

Enrolled (actual)
95
Serious AEs
1.1%
Results posted
Apr 2021
Primary outcome: Primary: The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System — 38; 96 Percentage of Adequate cleansing

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Pure-Vu System (Device)
Age
Adult, Older Adult · 22+ yrs
Sex
All
Sponsor
Motus GI Medical Technologies Ltd
Primary completion
May 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System
38; 96

Summary

The aim of this study is to evaluate the potential improvement in colonoscopy procedure's outcomes when using the Pure-Vu System in hospitalized patients who are indicated for colonoscopy procedure.

Eligibility Criteria

Inclusion Criteria

  • Hospitalized patients who are indicated for a screening, diagnostic, surveillance or therapeutic colonoscopy
  • Patients' age > 22 years
  • Patient has signed the informed consent

Exclusion Criteria

  • Patients with known Inflammatory Bowel Disease and / or active Colitis
  • Patients with active diverticulitis
  • Patients with known or detected (during colonoscopy) bowel obstruction
  • Patients with BMI ≤ 18
  • Patients with ascites Child Pugh C
  • Patients who are 30 days post-transplant
  • Patients treated with Peritoneal dialysis
  • Patients under active IV inotropic medications
  • Patients with LVAD
  • Patients who have active anticoagulant medications (excluding aspirin) or dual antiplatelet therapy in their system prior to the procedure. (Note: to avoid exclusion therapy should be discontinued 48 hours or greater prior to the procedure based on discretion of physician)
  • Subjects with known coagulation disorder (INR ≥ 2 or platelets <50,000)
  • Subjects with hemodynamic instability.
  • Pregnancy (as stated by patient) or breast feeding
  • Subjects with altered mental status/inability to provide informed consent
  • Patients who have participated in another interventional clinical study in the last 2 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03503162). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search